Blueprint Medicines
Precision therapy platform identifying and targeting genomic driver mutations in cancer and rare genetic diseases
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Latest Form D
- $50M, Nov 2014
- Total capital
- $73.2M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $73.2M
- 2 Form D · last Nov 2014
- 143 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 19
- 21 pending · first 2024
- Rank in peer group#4 of 342
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$50M
- Private capital raisedForm D · SEC · 1st filing$23.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
1 record has no date or no amount, so it isn’t placed on the timeline.
Standing among 342 peers
Line = medianBiotech · Platform
- Granted patents#4 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Alexis BorisyExecutive Officer, DirectorNamed in SEC Form D filings
- Christine W. BellonExecutive OfficerNamed in SEC Form D filings
- Christoph S. LengauerExecutive OfficerNamed in SEC Form D filings
- Daniel S. LynchDirectorNamed in SEC Form D filings
- David S. SchenkeinDirectorNamed in SEC Form D filings
- Jeffrey W. AlbersExecutive Officer, DirectorNamed in SEC Form D filings
Show all 11 people
- Kyle KuvalankaExecutive OfficerNamed in SEC Form D filings
- Nicholas S. LydonDirectorNamed in SEC Form D filings
- Nick S. LydonDirectorNamed in SEC Form D filings
- Stephen S. KnightDirectorNamed in SEC Form D filings
- Thilo S. SchroederDirectorNamed in SEC Form D filings
What it has protected
USPTO · 19 granted of 40- PendingBLU-945 In Combination With Osimertinib For The Treatment Of Non-small-cell Lung CancerUSPTOApplication 18849277
- PendingHeterocyclic Pan-kras InhibitorsUSPTOApplication 19535835
- GrantedSynthetic Methods And Intermediates For Producing Compounds For Treating Kit- And Pdgfra-mediated DiseasesUSPTOUS 12,698,290
Show all 40 patent records
- BLU-945 In Combination With Osimertinib For The Treatment Of Non-small-cell Lung CancerSep 10, 2026 · Application 18849277Pending
- Heterocyclic Pan-kras InhibitorsAug 27, 2026 · Application 19535835Pending
- Synthetic Methods And Intermediates For Producing Compounds For Treating Kit- And Pdgfra-mediated DiseasesAug 4, 2026 · US 12,698,290Granted
- Pyrimidine Compounds, Compositions, And Medicinal Applications ThereofJul 21, 2026 · US 12,686,673Granted
- Substituted Pyrimidinyl-pyrazoles As CDK2 InhibitorsJun 30, 2026 · US 12,668,585Granted
- Egfr InhibitorsJun 23, 2026 · US 12,662,465Granted
- Heterocyclic Egfr Inhibitors For Use In The Treatment Of CancerJun 16, 2026 · US 12,655,129Granted
- Process For Preparing An Activin Receptor-like Kinase InhibitorJun 16, 2026 · US 12,655,143Granted
- Pyrrolotriazine Derivatives For Treating Kit- And Pdgfra-mediated DiseasesMay 21, 2026 · Application 19456134Pending
- Compositions Useful For Treating Disorders Related To KitMay 12, 2026 · US 12,624,043Granted
- Crystalline Forms Of (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1- METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE And Methods Of MakingApr 30, 2026 · Application 18800215Pending
- MAP4K1 InhibitorsApr 16, 2026 · Application 19038199Pending
- Inhibitors Of Activin Receptor-like KinaseApr 7, 2026 · US 12,595,265Granted
- Inhibitors Of Protein Kinase AMar 24, 2026 · US 12,583,856Granted
- Wild Type Kit InhibitorsFeb 19, 2026 · Application 19302614Pending
- Pyrrolotriazine Derivatives For Treating Kit-and Pdgfra-mediated DiseasesFeb 17, 2026 · US 12,552,795Granted
- CDK2 InhibitorsFeb 10, 2026 · US 12,545,684Granted
- Wild Type Kit InhibitorsOct 21, 2025 · US 12,448,379Granted
- Egfr InhibitorsSep 18, 2025 · Application 18939072Pending
- Salt And Crystal Forms Of An Epidermal Growth Factor Receptor InhibitorSep 11, 2025 · Application 18862859Pending
- Kit InhibitorsAug 28, 2025 · Application 18858267Pending
- Egfr InhibitorsJul 24, 2025 · Application 18853933Pending
- Dosing Regimens Of (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZIN-1-YL)PYRIMIDIN-5-YL)ETHAN-1-AMINE For Treatment Of Indolent Systemic MastocytosisMar 18, 2025 · US 12,252,494Granted
- CDK2 Inhibitors And Methods Of Making And Using SameMar 6, 2025 · Application 18710715Pending
- MAP4K1 InhibitorsJan 21, 2025 · US 12,202,844Granted
- Egfr InhibitorsDec 24, 2024 · US 12,172,983Granted
- Methods For Treating Systemic Mastocytosis And Gastrointestinal Stromal TumorsNov 21, 2024 · Application 18199118Pending
- Heterocyclic Egfr Inhibitors For Use In The Treatment Of CancerNov 21, 2024 · Application 18572382Pending
- MAP4K1 InhibitorsOct 10, 2024 · Application 18578926Pending
- Process For Preparing Egfr InhibitorsSep 12, 2024 · Application 18573220Pending
- Heterocyclic Egfr Inhibitors For Use In The Treatment Of CancerSep 12, 2024 · Application 18572348Pending
- Egfr InhibitorsSep 12, 2024 · Application 18572867Pending
- Salt And Crystal Forms Of An Epidermal Growth Factor Receptor InhibitorSep 5, 2024 · Application 18573222Pending
- Crystalline Forms Of (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1-METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE And Methods Of MakingAug 13, 2024 · US 12,060,354Granted
- Salt And Solid Forms Of A Kinase InhibitorAug 1, 2024 · Application 18549769Pending
- MAP4K1 InhibitorsJul 23, 2024 · US 12,042,495Granted
- Diazepanone-fused Pyrimidine Compounds, Compositions And Medicinal Applications ThereofJul 4, 2024 · Application 18284943Pending
- MAP4K1 InhibitorsJun 20, 2024 · Application 18280900Pending
- Crystalline Forms Of (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1- METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE And Methods Of MakingJun 4, 2024 · US 11,999,744Granted
- CDK2 InhibitorsApr 30, 2024 · US 11,970,498Granted
Related companies, and why
- Comanche BiopharmaSimilar federal contract value in Biotech · null in contracts
- Expansion TherapeuticsSimilar federal contract value in Biotech · null in contracts
- SepternaSimilar federal contract value in Biotech · null in contracts
- Spark Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Kate TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Phosplatin Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .